Notice2022-09158
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 28, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 82 (Thursday, April 28, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 82 (Thursday, April 28, 2022)]
[Notices]
[Pages 25284-25285]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-09158]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
[[Page 25285]]
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or
<a href="/cdn-cgi/l/email-protection#e1a289938892cfaa8e938f808aa18f8889cf868e97"><span class="__cf_email__" data-cfemail="7a391208130954311508141b113a141312541d150c">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use
Description of Technology: National Institute of Allergy and
Infectious Diseases (NIAID), International AIDS Vaccine Initiative
(IAVI), Emergent, and Scripps have developed two recombinant adenovirus
type 4 (Ad4) vector-based vaccine candidates. These replicating Ad4
vector-based candidates have shown improved activity against tier 2
HIV-1 isolates in experimental animals. Tier 2 isolates are among the
most prevalent in infected populations. The two candidates, Ad4-
Env150KN and Ad4-Env145NFL, incorporate novel design features based on
Ad4-EnvC150 (1086c). Specifically, the truncation of the cytoplasmic
tail of Env increases cell surface expression and has resulted in
improved antigenicity from both candidates.
Additionally, the upper respiratory tract administration offers a
way to bypass pre-existing Ad4 immunity in most people. Furthermore,
unlike non-replicating vectors, these vaccines may evoke a durable
immune response.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Prophylaxis against HIV-1.
Competitive Advantages
<bullet> Replicating vector may invoke durable immunity against
HIV-1.
<bullet> Potential for prophylactic use in high-risk populations.
<bullet> Upper-respiratory (intranasal) administration will bypass
pre-existing Ad4 immunity in most people.
Development Stage
<bullet> Phase 1 Clinical Trial (NCT03878121).
Inventors: Mark Connors (NIAID), Jeff Alexander (Emergent), Lo Vang
(Emergent), Richard Wyatt (Scripps and IAVI), and Javier Guenaga
(IAVI).
Publications: Alexander J., Mendy J., Vang L., Avanzini J.B.,
Garduno F., et al. (2013) Pre-Clinical Development of a Recombinant,
Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing
HIV-1 Envelope 1086 Clade C. PLOS ONE 8(12): e82380. <a href="https://doi.org/10.1371/journal.pone.0082380">https://doi.org/10.1371/journal.pone.0082380</a>.
Intellectual Property: HHS Reference No. E-105-2020-0-PCT-01--PCT
Application No. PCT/US21/45389 filed on 10 August 2021.
Licensing Contact: To license this technology, please contact Chris
Kornak at 240-627-3705 or <a href="/cdn-cgi/l/email-protection#63200b110a104d280c110d0208230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="eba883998298c5a08499858a80ab858283c58c849d">[email protected]</span></a>, and reference E-105-
2020.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. In particular,
NIAID would be very interested in a partnership with an entity that has
a complementary HIV vaccine technology. For collaboration
opportunities, please contact Chris Kornak at 240-627-3705 or
<a href="/cdn-cgi/l/email-protection#2b684359425805604459454a406b454243054c445d"><span class="__cf_email__" data-cfemail="0e4d667c677d2045617c606f654e60676620696178">[email protected]</span></a>.
Dated: April 25, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-09158 Filed 4-27-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 28, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.